
Full text loading...
Category: Immunology
Parvovirus B19, Page 1 of 2
< Previous page | Next page > /docserver/preview/fulltext/10.1128/9781555818722/9781555818715_CH62-1.gif /docserver/preview/fulltext/10.1128/9781555818722/9781555818715_CH62-2.gifAbstract:
Autonomous parvoviruses capable of helper-virus-independent replication have been isolated from many animal species. The human serum parvovirus B19 was accidentally discovered in 1975 in healthy donor blood used in the development of hepatitis B virus surface antigen diagnostic tests. To date, three B19-type genotypes have been described: types 1 (B19), 2 (A6/K71), and 3 (V9). Disease variation has not been reported amongst the three genotypes (1–3). Bocavirus, another parvovirus, has been associated with pulmonary infection (4). PARV4 has been identified in a parenteral drug abuser, but human disease causation has not been confirmed (5, 6). Recently, a proposal was submitted to the International Committee on Taxonomy of Viruses to reclassify B19 as primate erythroparvovirus type 1. The most frequent clinical presentation of B19 infection is erythema infectiosum, or fifth disease, a common childhood exanthem. Application of sensitive molecular biological and immunological methods to viral diagnosis has allowed recognition of the ever-expanding spectrum of clinical presentation (7).
Full text loading...
Electron micrograph of serum from a patient with sickle cell disease and aplastic crisis, showing full (white arrow) and empty (black arrow) nonenveloped, icosahedral viral particles measuring ∼23 nm in diameter, visualized by negative staining with uranyl acetate. Bar, 100 nm (original magnification, ×196,000). Reprinted from reference 26 with permission of the publisher.
Electron micrograph of serum from a patient with sickle cell disease and aplastic crisis, showing full (white arrow) and empty (black arrow) nonenveloped, icosahedral viral particles measuring ∼23 nm in diameter, visualized by negative staining with uranyl acetate. Bar, 100 nm (original magnification, ×196,000). Reprinted from reference 26 with permission of the publisher.
ELISA-based tests showing antibody capture ELISA for anti-B19 IgM antibody (A), antibody capture ELISA for anti-B19 IgG antibody (B), antigen capture ELISA for B19 virus (C), and recombinant or synthetic B19 antigen-based ELISA for detection of B19 antibody (D).
ELISA-based tests showing antibody capture ELISA for anti-B19 IgM antibody (A), antibody capture ELISA for anti-B19 IgG antibody (B), antigen capture ELISA for B19 virus (C), and recombinant or synthetic B19 antigen-based ELISA for detection of B19 antibody (D).
Common clinical presentations of parvovirus B19 infection
Common clinical presentations of parvovirus B19 infection
Less common clinical presentations of parvovirus B19 infection
Less common clinical presentations of parvovirus B19 infection